We are a clinical-stage biotherapeutics company focused on developing innovative therapies that address significant unmet medical needs in the treatment of cardiopulmonary diseases. We are currently developing three product candidates under our INOpulse platform, a proprietary pulsatile nitric oxide drug delivery system. The first is for the treatment of pulmonary hypertension associated with interstitial lung disease (PH-ILD). The second product candidate is for the treatment of pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD) and the third is for the treatment of pulmonary hypertension associated with sarcoidosis (PH-Sarc). All three of our programs are in Phase 2 development.